SAMR doubles down on excessive pricing enforcement in pharma sector
Shutterstock/PhotobyTawat
China’s competition watchdog has fined a drugmaker nearly €3.7 million for hiking the price of a “gold standard” cancer treatment by 750% despite production costs allegedly remaining stable.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Subscribe now